Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 15/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 15/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 15/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3533400 | 0.94 | MAPK14 (0.95) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL13741201 | 0.94 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL28942120 | 0.94 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL4054088 | 0.92 | MAPK14 (0.86) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL16866510 | 0.90 | MAPK13 (0.83) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL13234634 | 0.89 | MAPK14 (0.91) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL12245421 | 0.88 | MAPK14 (0.88) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL5474153 | 0.88 | MAPK14 (0.88) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| Hydrochloric Acid SCHEMBL3533699 | 0.87 | MAPK14 (0.86) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL1600309 | 0.87 | CDK8 (0.82) | MAPK14MAPK13MAPK12MAPK11PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624196-B2 | Inhibitor of p38 MAP kinase | RESPIVERT LTD. (GB) | 2017-04-18 | — | — | US | disclosed |
| US-20160368896-A1 | INHIBITOR OF p38 MAP KINASE | RESPIVERT LIMITED (GB) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368896-A1 | INHIBITOR OF p38 MAP KINASE | MAPK1, MAPK4, MAPK8 | MAPK14 13/4885MAPK13 10/4885MAPK12 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.